VisionSys AI Inc is a holding company primarily engaged in the development of brain-computer interface (BCI) technologies and related businesses. The Company's main business is developing, procuring, selling, and distributing BCI-enabled or BCI-adjacent products and solutions, and to provide related technical services. The BCI technologies are used in medical and healthcare-related applications, including functional rehabilitation, communication support, neurological disease-related monitoring and intervention, sensory assistance, and general wellness management. The Company mainly operates its businesses in the domestic market.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-06-18	4.580 $	-5.57%	36,166
26-06-17	4.850 $	-3.00%	38,857
26-06-16	5.000 $	+1.01%	45,404
26-06-15	4.950 $	+8.08%	100,887
26-06-12	4.580 $	+5.05%	110,333

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Market Closed - Nasdaq Other stock markets 16:00:00 2026-06-18 EDT			5-day change	1st Jan Change
4.580 ^USD	-5.57%		0.00%	-81.15%

06-02	Top Premarket Gainers	MT
05-11	VisionSys AI Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Market Cap	19.24M 2.84M 2.48M 2.3M 2.15M 4.03M 268M 4.05M 27.23M 10.55M 132M 10.67M 10.44M 458M	P/E 2024	-0.09x	P/E 2025	0.01x
Enterprise Value	-34.2M -5.05M -4.41M -4.08M -3.82M -7.16M -477M -7.21M -48.41M -18.76M -235M -18.97M -18.56M -815M	EV / Sales 2024	0.22x	EV / Sales 2025	-34.3x
Free-Float	13.7%	Yield 2024 *	-	Yield 2025	-

06-02	Top Premarket Gainers	MT
05-11	VisionSys AI Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
05-05	Visionsys Ai Inc - to change ADS ratio from 1:250 to 1:2500 effective May 26, 2026	RE
05-05	Visionsys Ai Inc - to change ADS ratio from 1:250 to 1:2500 class A ordinary shares	RE
04-28	Asian Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading	MT
04-27	VisionSys AI announces proposed $90 million strategic investment at $1.50/share	RE
04-26	VisionSys AI Inc. announced that it expects to receive $90 million in funding	CI
03-27	Wall Street Set to Open Lower in Friday Trading; Investors Not Assuaged by US Deadline Extension for Iran to Open Strait of Hormuz	MT
03-13	Certain American Depositary Shares of VisionSys AI Inc. are subject to a Lock-Up Agreement Ending on 14-MAR-2026.	CI
03-13	Certain Class A Ordinary Shares of VisionSys AI Inc. are subject to a Lock-Up Agreement Ending on 14-MAR-2026.	CI
03-13	Certain Warrants of VisionSys AI Inc. are subject to a Lock-Up Agreement Ending on 14-MAR-2026.	CI
03-10	VisionSys AI Inc. announced that it expects to receive $30.21 million in funding	CI
02-12	VisionSys AI Inc. Announces Changes in Board and Committee Member	CI

25-10-24	VisionSys AI Inc Announces Board Changes	CI
23-06-14	EF Hutton Adjusts Price Target on Tarena International to $8 From $11, Keeps Buy Rating	MT
23-03-29	EF Hutton Adjusts Price Target on Tarena International to $11 From $12, Maintains Buy Rating	MT
23-02-27	EF Hutton Initiates Coverage on Tarena International With Buy Rating, $12 Price Target	MT

VisionSys AI Inc. Stock

Stocks

VSA

US8761084081

Biotechnology & Medical Research

Valuation: VisionSys AI Inc.

Chart: VisionSys AI Inc.

Latest news : VisionSys AI Inc.

Analysts' recommendations: VisionSys AI Inc.

Press Releases: VisionSys AI Inc.

Quotes and Performance

Course Extremes

Managers and Directors: VisionSys AI Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

05-20	VisionSys AI Inc Announces ADS Ratio Change with Marketplace Effective Date on May 26, 2026	GL
05-05	VisionSys AI Inc Announces Planned ADS Ratio Change	GL
05-05	VisionSys AI Inc Announces Planned ADS Ratio Change	AQ
04-27	VisionSys AI Inc. Announces Proposed $90 Million Strategic Investment at $1.50 Per Share	GL
03-27	VisionSys AI Inc. Announces Pricing of $3 Million Registered Direct Offering	GL

1 day	-5.57%
Current month	+17.89%
1 month	+50.61%
3 months	-31.75%
6 months	-87.01%
Current year	-81.15%

1 week	4.5	5.12
1 month	3.01	7.71
Current year	2.81	33.65
1 year	2.81	2,120.35
3 years	2.81	2,120.35
5 years	2.81	8,000
10 years	2.81	54,250

Manager	Title	Age	Since
Tian Long Wang CEO	Chief Executive Officer	40	2025-12-04
Diyu Jiang DFI	Director of Finance/CFO	-	2025-12-04
Ying Sun CEO	Chief Executive Officer	50	2021-04-07

Director	Title	Age	Since
Jian Guang Li BRD	Director/Board Member	61	2014-03-31
Ming Jie Sun BRD	Director/Board Member	62	2022-11-30
WU Xiaoxia BRD	Director/Board Member	-	2025-12-04

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
VISIONSYS AI INC.	-5.57%	0.00%	-99.12%	-99.71%	2.85M
LONZA GROUP AG	+1.44%	+1.71%	-10.63%	-9.16%	43.13B
REVOLUTION MEDICINES, INC.	+3.31%	+5.93%	+308.19%	+562.02%	34.65B
BEONE MEDICINES AG	+2.84%	+2.14%	+6.87%	+34.93%	30.03B
IQVIA HOLDINGS INC.	-1.70%	-7.54%	+8.51%	-22.34%	28B
CELLTRION, INC.	-1.90%	-1.56%	+11.62%	+19.80%	24.45B
ASCENDIS PHARMA A/S	-0.14%	+5.86%	-	-	14.34B
MEDPACE HOLDINGS, INC.	+0.68%	-1.53%	+52.04%	+107.47%	13.14B
EUROFINS SCIENTIFIC SE	-0.57%	-2.43%	+5.18%	+4.20%	12.53B
IONIS PHARMACEUTICALS, INC.	-0.26%	+1.15%	+100.27%	+80.69%	12.25B
Average	-0.19%	+1.17%	+42.55%	+75.32%	21.25B
Weighted average by Cap.	+0.77%	+1.27%	+65.22%	+113.22%

	2024	2025
Net sales	1.17B 173M 151M 140M 131M 245M 16.32B 247M 1.66B 642M 8.03B 649M 635M 27.9B	1.04M 154K 134K 124K 116K 218K 14.48M 219K 1.47M 570K 7.13M 576K 564K 24.75M
Net income	-587M -86.66M -75.55M -69.98M -65.51M -123M -8.18B -124M -830M -322M -4.02B -325M -318M -13.97B	1.72B 254M 221M 205M 192M 360M 23.96B 362M 2.43B 943M 11.79B 953M 933M 40.95B
Net Debt	208M 30.71M 26.78M 24.8M 23.22M 43.55M 2.9B 43.81M 294M 114M 1.43B 115M 113M 4.95B	-53.44M -7.9M -6.88M -6.38M -5.97M -11.19M -745M -11.26M -75.64M -29.32M -367M -29.64M -29M -1.27B